Minerva Neurosciences, Inc.
May 4, 2017

Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates

WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2017.

"We recently had a meeting with the U.S. Food and Drug Administration (FDA) to obtain feedback and guidance related to the Phase III clinical development of MIN-101 as a treatment for negative symptoms of schizophrenia," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "We expect to initiate Phase III development of this compound in the second half of 2017."

Clinical Development Updates

MIN-101:

MIN-117:

MIN-202 (JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

First Quarter 2017 Financial Results

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 2971783.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones with MIN-101, MIN-202 and MIN-117, including the planned Phase III trial of MIN-101, the timing and scope of future clinical trials and results of clinical trials with these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether any of our therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of any of our therapeutic products, if any, will be consistent with the results of past clinical trials; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 4, 2017.  Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.



CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
 March 31,December 31,
 2017  2016 
 (in thousands)
ASSETS
Current Assets:  
Cash and cash equivalents$  68,895 $  82,981 
Marketable securities   16,465    -  
Restricted cash   80    80 
Prepaid expenses and other current assets   792     803 
Total current assets   86,232    83,864 
Equipment, net   6    10 
In-process research and development   34,200    34,200 
Goodwill   14,869    14,869 
Total Assets$  135,307  $  132,943 
   
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:  
Notes payable - current portion$  4,959 $  4,854 
Accounts payable   3,276    1,467 
Accrued expenses and other current liabilities   1,673    816 
       
Accrued collaborative expenses   3,078    2,548 
       
Total current liabilities   12,986    9,685 
   
Long-Term Liabilities:  
Notes payable - noncurrent   2,601    3,841 
Deferred taxes    13,434    13,434 
Total liabilities   29,021    26,960 
Stockholders' Equity:  
Common stock    4    4 
Additional paid-in capital   249,785    238,837 
Accumulated deficit   (143,503)   (132,858)
Total stockholders' equity   106,286    105,983 
Total Liabilities and Stockholders' Equity$  135,307 $  132,943 


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)   
  Three Months Ended March 31,
   
  (in thousands, except per share amounts)
   2017  2016 
    
Revenues $  -  $  -  
Operating expenses:   
Research and development    7,614    5,375 
General and administrative    2,871    2,382 
Total operating expenses    10,485    7,757 
    
Foreign exchange losses    (17)   (9)
Investment income    59    32 
Interest expense    (202)   (270)
Net loss $  (10,645)$  (8,004)
Loss per share:   
Basic and diluted $  (0.30)$  (0.29)
Weighted average shares:   
Basic and diluted    35,370    27,203 

 

Contact:



William B. Boni

VP, Investor Relations/

Corp. Communications

Minerva Neurosciences, Inc.

(617) 600-7376

Primary Logo

Source: Minerva Neurosciences, Inc.

News Provided by Acquire Media